5 recruiting, 4 active not recruiting, 4 unknown, 1 not yet recruiting. 8 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 2, Recruiting 2, Unknown 2, Not yet recruiting 1, Withdrawn 1 |
| Not applicable | 2 | Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Neoadjuvant Treatment: new trials by email Literature Review of Neoadjuvant Treatment trials Research Report on Neoadjuvant Treatment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Administration of Artificial Nutrition by Feeding Jejunostomy During Neoadjuvant Treatment on Postoperative Morbidity in the Context of Esophageal or Stomach Cancer Enteral or parenteral nutrition - Esophageal Cancer, Surgery Indication | Recruiting | University Hospital, Bordeaux | 670 | 2026-11-01 | 2026-05-13 | |
| Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery Zanzalintinib - Neoadjuvant Treatment, Thyroid Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 45 | 2025-07-22 | 2026-09-04 |
| Impact of "Targeted" Nutritional Apport and Exercise on the Modulation of Metabolic and Immune-related Gene Expression Signatures in Early Breast Cancer (eBC) Patients Candidate to Neoadjuvant Therapy (NAT) omega-3 (n-3 Lc-PUFA), EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) plus a source of palmitoleic acid (hexadecenoic acid) - Early Breast Cancer, Neoadjuvant Treatment | Not applicable | Recruiting | University of Eastern Piedmont | 160 | 2024-09-01 | 2025-04-15 |
| Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib, Esophagectomy, Collecting samples from participant - Esophageal Squamous Cell Carcinoma, Neoadjuvant Treatment | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 35 | 2024-08-08 | 2025-12-02 |
| Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer Anlotinib+Capeox, Capeox - Neoadjuvant Treatment, Rectal Cancer | Phase 2 | Withdrawn | Shanghai Minimally Invasive Surgery Center | 2023-11-01 | 2021-09-28 | |
| Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer Blood sample, MRI scan - Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment | Active not recruiting | Jena University Hospital | 40 | 2022-11-30 | 2026-08-06 | |
| Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy Bevacizumab+mFOLFOX6 - Neoadjuvant Treatment, Rectal Cancer | Phase 1 / Phase 2 | Unknown | Shanghai Minimally Invasive Surgery Center | 20 | 2022-11-01 | 2024-03-07 |
| Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment | Active not recruiting | Fundación GECP | 100 | 2022-06-17 | 2025-11-19 | |
| The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC Tislelizumab, Low-dose radiotherapy - Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment | Phase 2 | Active not recruiting | Fifth Affiliated Hospital, Sun Yat-Sen University | 25 | 2022-03-09 | 2026-09-09 |
| Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy cetuximab+mFOLFOX6, short-course radiotherapy - Neoadjuvant Treatment, Rectal Cancer | Unknown | Shanghai Minimally Invasive Surgery Center | 51 | 2021-10-20 | 2024-02-26 | |
| Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma Lenvatinib, Pembrolizumab - Mucosal Melanoma, Neoadjuvant Treatment | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 26 | 2020-12-30 | 2020-11-13 |
| Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma Neoadjuvant immunochemotherapy - Esophageal Cancer, Surgery | Phase 3 | Recruiting | Henan Cancer Hospital | 400 | 2020-04-21 | 2022-10-04 |
| Adaptive Individualized High-Dose Radiotherapy Analysis-REctum-1 (AIDA-RE-1) IMRT-SIB plus sequential IG-RT boost - Rectal Cancer, Radiotherapy | Not applicable | Unknown | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 9 | 2016-08-01 | 2018-03-27 |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Olaparib, Platinum-based Chemotherapy - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Active not recruiting | University Health Network, Toronto | 71 | 2016-07-19 | 2026-06-23 |
| Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer Cetuximab, Irinotecan, Capecitabine - Rectal Neoplasms, Neoadjuvant Treatment | Phase 2 | Unknown | National Cancer Center, Korea | 40 | 2006-05-01 | 2007-07-25 |
Rectal Neoplasms (6) · Esophageal Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Squamous Cell Carcinoma (1) · Fallopian Tube Neoplasms (1) · Malnutrition (1) · Neoplastic Cells, Circulating (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Thyroid Neoplasms (1)
Neoplasms (14) · Neoplasms by Site (14) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Gastrointestinal Diseases (9) · Gastrointestinal Neoplasms (9) · Colorectal Neoplasms (6) · Intestinal Diseases (6) · Intestinal Neoplasms (6) · Rectal Diseases (6) · Head and Neck Neoplasms (5) · Esophageal Diseases (3) · Carcinoma (2) · Carcinoma, Squamous Cell (2) · Endocrine Gland Neoplasms (2)
Albumin-Bound Paclitaxel (1) · Blood Specimen Collection (1) · Capecitabine (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Docosahexaenoic Acids (1) · Eicosapentaenoic Acid (1) · Esophagectomy (1) · Irinotecan (1) · Magnetic Resonance Imaging (1) · Parenteral Nutrition (1) · Platinum Compounds (1) · Radiotherapy (1) · apatinib (1)
Shanghai Minimally Invasive Surgery Center (3) · Fifth Affiliated Hospital, Sun Yat-Sen University (1) · Fundación GECP (1) · Henan Cancer Hospital (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Jena University Hospital (1) · M.D. Anderson Cancer Center (1) · National Cancer Center, Korea (1) · Peking University Cancer Hospital & Institute (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · University Health Network, Toronto (1) · University Hospital, Bordeaux (1) · University of Eastern Piedmont (1)
China (6) · Italy (2) · Spain (2) · Canada (1) · France (1) · Germany (1) · New Zealand (1) · South Korea (1) · United Kingdom (1) · United States (1)
Alessandra Gennari, MD (1) · Alessio G Morganti, MD (1) · Amit Oza, M.D. (1) · Andrea Wittig-Sauerwein, MD (1) · Jun Guo, MD (1) · Kyung Hae Jung, M.D.Ph.D (1) · Mariano Provencio, MD (1) · Mark Zafereo, MD (1) · Yan Zheng, PhD, MD (1)